Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 13
Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
Authors AlDallal SM
Received 20 April 2017
Accepted for publication 26 June 2017
Published 20 July 2017 Volume 2017:13 Pages 905—907
DOI https://doi.org/10.2147/TCRM.S140023
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Lucy Goodman
Peer reviewer comments 2
Editor who approved publication: Professor Garry Walsh
Salma M AlDallal
Haematology Laboratory, Amiri Hospital, Kuwait City, Kuwait
Abstract: Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. This article summarizes this antibody’s therapeutic effect on chronic lymphocytic leukemia.
Keywords: ofatumumab, cell-mediated cytotoxicity, chronic lymphocytic leukemia
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.